From Chronic to Blast: How Diagnostic Delay Shapes Outcomes in MLN-FGFR1 (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-1345; Location: LEVEL 3, HALL B3; "The near-complete response in chronic phase vs 44% in blast phase argues that earlier diagnosis directly expands therapeutic opportunity in MLN-FGFR1. Nearly half of patients with chronicphase disease transform within a year, yet early presentations are often difficult to classify. A lower threshold for FGFR1 FISH testing in phenotypically ambiguous presentations, particularly BCR::ABL1-negative myeloproliferative disease or T-lymphoblastic lymphoma with marrow involvement, could meaningfully shift the phase at which patients are detected."
Hematological Malignancies • Leukemia • Lymphoblastic Lymphoma • Lymphoma • Myeloproliferative Neoplasm • Oncology • ABL1 • BCR • FGFR1
|